Granulomatose mit Polyangiitis und mikroskopische Polyangiitis

Zusammenfassung

Die Granulomatose mit Polyangiitis (GPA) und mikroskopische Polyangiitis (MPA) sind zwei zur ANCA-assoziierten Vaskulitis (AAV) zählende Entitäten. Beiden Erkrankungen liegt eine systemische nekrotisierende Kleingefäßvaskulitis zugrunde, die jedes Organ betreffen kann. Bei der GPA ist zusätzlich eine in der Regel den Respirationstrakt betreffende extravaskuläre nekrotisierende granulomatöse Entzündung vorzufinden. Das klinische Bild wird in der Mehrzahl der Fälle durch ein pulmo-renales Syndrom mit alveolärer Hämorrhagie und rapid-progressiver Glomerulonephritis sowie weitere Organmanifestationen bestimmt. Bei der GPA imponiert zudem die fast regelhafte Mitbeteiligung des oberen Respirationstrakts. Die GPA ist mit Anti-Neutrophilen zytoplasmatischen Autoantikörpern (ANCA) mit einer Spezifität für die Proteinase 3 (PR3-ANCA) und die MPA für Myeloperoxidase (MPO-ANCA) assoziiert. Die immunsuppressive Therapie richtet sich nach der Krankheitsaktivität und Schwere der Organbeteiligung.

Abstract

Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are two entities of ANCA-associated vasculitis (AAV). Both diseases are characterised by systemic necrotising small-vessel vasculitis, which can affect any organ. In GPA, extravascular necrotising granulomatous inflammation, usually affecting the respiratory tract, is found in addition. In the majority of cases, the clinical presentation is dominated by a pulmonary-renal syndrome with alveolar haemorrhage and rapidly progressive glomerulonephritis. Other organ involvement is found as well. In GPA, the upper respiratory tract is commonly affected. GPA is associated with anti-neutrophil cytoplasmic autoantibodies (ANCA) with specificity for proteinase 3 (PR3-ANCA) and MPA with specificity for myeloperoxidase (MPO-ANCA). Immunosuppressive therapy depends on disease activity and the severity of organ involvement.

Schlüsselwörter

ANCA - Vaskulitis - AAV - Granulomatose mit Polyangiitis - Mikroskopische Polyangiitis

Key words

ANCA - AAV - vasculitis - granulomatosis with polyangiitis - microscopic polyangiitis

Publication History

Article published online:
21 November 2022

• Literatur

• 1 Jennette JC, Falk RJ, Bacon PA. et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65: 1-11 DOI: 10.1002/art.37715.
• 2 Lamprecht P, Kerstein A, Klapa S. et al. Pathogenetic and Clinical Aspects of Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitides. Front Immunol 2018; 9: 680 DOI: 10.3389/fimmu.2018.00680.
• 3 Kitching AR, Anders HJ, Basu N. et al. ANCA-associated vasculitis. Nat Rev Dis Primers 2020; 6: 71 DOI: 10.1038/s41572-020-0204-y.
• 4 Hellmich B. Update of the EULAR recommendations on the management of ANCA-associated vasculitis. EULAR recommendations session. EULAR 2022 congress; Copenhagen: 01.06.2022
• 5 Mahr A, Specks U, Jayne D. Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum. Rheumatology (Oxford) 2019; 58: 1707-1709 DOI: 10.1093/rheumatology/kez148.
• 6 Lamprecht P, Müller A, Witko-Sarsat V. et al. Comment on: Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum. Rheumatology (Oxford) 2020; 59: 1185-1187 DOI: 10.1093/rheumatology/keaa068.
• 7 Banerjee S, Grayson PC. Vasculitis Around the World: Epidemiologic Insights into Causality and a Need for Global Partnerships. J Rheumatol 2017; 44: 136-139 DOI: 10.3899/jrheum.161468.
• 8 Hellmich B, Lamprecht P, Spearpoint P. et al. New insights into the epidemiology of ANCA-associated vasculitides in Germany: results from a claims data study. Rheumatology (Oxford) 2021; 60: 4868-4873 DOI: 10.1093/rheumatology/keaa924.
• 9 Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 1958; 2: 265-270 DOI: 10.1136/bmj.2.5091.265.
• 10 Flossmann O, Berden A, de Groot K. et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011; 70: 488-494 DOI: 10.1136/ard.2010.137778.
• 11 Tan JA, Dehghan N, Chen W. et al. Mortality in ANCA-associated vasculitis: a meta-analysis of observational studies. Ann Rheum Dis 2017; 76: 1566-1574 DOI: 10.1136/annrheumdis-2016-210942.
• 12 Müller A, Krause B, Kerstein-Stähle A. et al. Granulomatous Inflammation in ANCA-Associated Vasculitis. Int J Mol Sci 2021; 22: 6474 DOI: 10.3390/ijms22126474.
• 13 Arnold S, Holl-Ulrich K, Müller A. et al. Update Ätiopathogenese der Kleingefäßvaskulitis. Z Rheumatol 2022; 81: 270-279 DOI: 10.1007/s00393-021-01155-4.
• 14 Arnold S, Klapa S, Holl-Ulrich K. et al. Granulomatöse Vaskulitiden und Vaskulitiden mit extravaskulärer Granulomatose. Z Rheumatol 2022; 10 DOI: 10.1007/s00393-022-01249-7.
• 15 Rahmattulla C, Mooyaart AL, van Hooven D. et al. Genetic variants in ANCA-associated vasculitis: a meta-analysis. Ann Rheum Dis 2016; 75: 1687-1692 DOI: 10.1136/annrheumdis-2015-207601.
• 16 Jones BE, Yang J, Muthigi A. et al. Gene-Specific DNA Methylation Changes Predict Remission in Patients with ANCA-Associated Vasculitis. J Am Soc Nephrol 2017; 28: 1175-1187 DOI: 10.1681/ASN.2016050548.
• 17 Millet A, Martin KR, Bonnefoy F. et al. Proteinase 3 on apoptotic cells disrupts immune silencing in autoimmune vasculitis. J Clin Invest 2015; 125: 4107-4121 DOI: 10.1172/JCI78182.
• 18 Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol 2014; 10: 463-473 DOI: 10.1038/nrrheum.2014.103.
• 19 Everts-Graber J, Martin KR, Thieblemont N. et al. Proteomic analysis of neutrophils in ANCA-associated vasculitis reveals a dysregulation in proteinase 3-associated proteins such as annexin-A1 involved in apoptotic cell clearance. Kidney Int 2019; 96: 397-408 DOI: 10.1016/j.kint.2019.02.017.
• 20 Rovere-Querini P, Capobianco A, Scaffidi P. et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004; 5: 825-830 DOI: 10.1038/sj.embor.7400205.
• 21 Muñoz LE, Lauber K, Schiller M. et al. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 2010; 6: 280-289 DOI: 10.1038/nrrheum.2010.46.
• 22 Schreiber A, Rousselle A, Becker JU. et al. Necroptosis controls NET generation and mediates complement activation, endothelial damage, and autoimmune vasculitis. Proc Natl Acad Sci U S A 2017; 114: E9618-E9625 DOI: 10.1073/pnas.1708247114.
• 23 Weppner G, Ohlei O, Hammers CM. et al. In situ detection of PR3-ANCA⁺B cells and alterations in the variable region of immunoglobulin genes support a role of inflamed tissue in the emergence of auto-reactivity in granulomatosis with polyangiitis. J Autoimmun 2018; 93: 89-103 DOI: 10.1016/j.jaut.2018.07.004.
• 24 Salama AD, Little MA. Animal models of antineutrophil cytoplasm antibody-associated vasculitis. Curr Opin Rheumatol 2012; 24: 1-7 DOI: 10.1097/BOR.0b013e32834d2d52.
• 25 Lamprecht P, Fischer N, Huang J. et al. Changes in the composition of the upper respiratory tract microbial community in granulomatosis with polyangiitis. J Autoimmun 2019; 97: 29-39 DOI: 10.1016/j.jaut.2018.10.005.
• 26 Laudien M, Gadola SD, Podschun R. et al. Nasal carriage of Staphylococcus aureus and endonasal activity in Wegener s granulomatosis as compared to rheumatoid arthritis and chronic Rhinosinusitis with nasal polyps. Clin Exp Rheumatol. 2010; 28: 51-55
• 27 Holle JU, Gross WL, Latza U. et al. Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 2011; 63: 257-266 DOI: 10.1002/art.27763.
• 28 Schirmer JH, Wright MN, Vonthein R. et al. Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort. Rheumatology (Oxford) 2016; 55: 71-79 DOI: 10.1093/rheumatology/kev286.
• 29 Holle JU, Gross WL, Holl-Ulrich K. et al. Prospective long-term follow-up of patients with localised Wegener's granulomatosis: does it occur as persistent disease stage?. Ann Rheum Dis 2010; 69: 1934-1939 DOI: 10.1136/ard.2010.130203.
• 30 Holl-Ulrich K. Histopathologie systemischer Vaskulitiden. Pathologe 2010; 31: 67-76 DOI: 10.1007/s00292-009-1156-x.
• 31 Specks U, Merkel PA, Seo P. et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013; 369: 417-427 DOI: 10.1056/NEJMoa1213277.
• 32 Luqmani RA. Disease assessment in systemic vasculitis. Nephrol Dial Transplant 2015; 30: i76-i82 DOI: 10.1093/ndt/gfv002.
• 33 Bossuyt X, Cohen Tervaert JW, Arimura Y. et al. Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol 2017; 13: 683-692 DOI: 10.1038/nrrheum.2017.140.
• 34 Rovin BH, Adler SG, Barratt J. et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int 2021; 100: 753-779 DOI: 10.1016/j.kint.2021.05.015.
• 35 Brix SR, Noriega M, Tennstedt P. et al. Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int 2018; 94: 1177-1188 DOI: 10.1016/j.kint.2018.07.020.
• 36 Kronbichler A, Jayne DRW. ANCA Renal Risk Score: is prediction of end-stage renal disease at baseline possible?. Kidney Int 2018; 94: 1045-1047 DOI: 10.1016/j.kint.2018.10.001.
• 37 Robson JC, Grayson PC, Ponte C. et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis 2022; 81: 315-320 DOI: 10.1136/annrheumdis-2021-221795.
• 38 Suppiah R, Robson JC, Grayson PC. et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Ann Rheum Dis 2022; 81: 321-326 DOI: 10.1136/annrheumdis-2021-221796.
• 39 Mukhtyar C, Lee R, Brown D. et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009; 68: 1827-1832 DOI: 10.1136/ard.2008.101279.
• 40 DeRemee RA, McDonald TJ, Harrison EG. et al. Wegener's granulomatosis. Anatomic correlates, a proposed classification. Mayo Clin Proc 1976; 51: 777-781
• 41 de Groot K, Gross WL, Herlyn K. et al. Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol 2001; 55: 31-38
• 42 Exley AR, Bacon PA, Luqmani RA. et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997; 40: 371-380 DOI: 10.1002/art.1780400222.
• 43 Jones RB, Tervaert JW, Hauser T. et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363: 211-220 DOI: 10.1056/NEJMoa0909169.
• 44 Stone JH, Merkel PA, Spiera R. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-232 DOI: 10.1056/NEJMoa0909905.
• 45 McAdoo SP, Medjeral-Thomas N, Gopaluni S. et al. Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrol Dial Transplant 2019; 34: 63-73 DOI: 10.1093/ndt/gfx378.
• 46 Schinke S, Riemekasten G, Lamprecht P. Therapiedeeskalation bei ANCA-assoziierten Vaskulitiden. Z Rheumatol 2017; 76: 15-20 DOI: 10.1007/s00393-016-0241.
• 47 Walsh M, Merkel PA, Peh CA. et al. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N Engl J Med 2020; 382: 622-631 DOI: 10.1056/NEJMoa1803537.
• 48 Smith RM, Jones RB, Specks U. et al. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis 2020; 79: 1243-1249 DOI: 10.1136/annrheumdis-2019-216863.
• 49 Chung SA, Langford CA, Maz M. et al. 2021; American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2021 Aug 73: 1366-1383 DOI: 10.1002/art.41773..
• 50 Casal Moura M, Irazabal MV, Eirin A. et al. Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease. J Am Soc Nephrol 2020; 31: 2688-2704 DOI: 10.1681/ASN.2019111197.
• 51 Walsh M, Collister D, Zeng L. et al. The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis. BMJ 2022; 376: e064604 DOI: 10.1136/bmj-2021-064604.
• 52 Jayne DRW, Merkel PA, Schall TJ. et al. Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med 2021; 384: 599-609 DOI: 10.1056/NEJMoa2023386.
• 53 De Groot K, Rasmussen N, Bacon PA. et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52: 2461-2469 DOI: 10.1002/art.21142.
• 54 Guillevin L, Pagnoux C, Karras A. et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014; 371: 1771-1780 DOI: 10.1056/NEJMoa1404231.
• 55 Charles P, Terrier B, Perrodeau É. et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis 2019; 78: e101
• 56 Cornec D, Berti A, Hummel A. et al. Identification and phenotyping of circulating autoreactive proteinase 3-specific B cells in patients with PR3-ANCA associated vasculitis and healthy controls. J Autoimmun 2017; 84: 122-131 DOI: 10.1016/j.jaut.2017.08.006.
• 57 Charles P, Perrodeau É, Samson M. et al. Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial. Ann Intern Med 2020; 173: 179-187 DOI: 10.7326/M19-3827.
• 58 Schirmer JH, Aries PM, de Groot K. et al. S1-Leitlinie Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden. Z Rheumatol 2017; 76: 77-104 DOI: 10.1007/s00393-017-0394-1.